We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

A by D Introduces a Series of HuCAL GOLD® Recombinant Antibodies


Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "A by D Introduces a Series of HuCAL GOLD® Recombinant Antibodies"

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:
 

Antibodies by Design, a division of MorphoSys AG, has announced the launch of a series of fully human, recombinant research antibodies from the HuCAL GOLD® antibody library into the sales catalog of the Biogenesis group.

These recombinant research antibodies were identified and developed as part of ongoing research cooperations and from proactive projects at Biogenesis for targets with significant demand from potential clients.

The range of targets include the bone matrix protein osteocalcin, cyclophilin A, a part of the cell’s protein folding apparatus, and the tyrosine protein kinase EphB4, which plays a role in mediating developmental events particularly in the nervous system and production of which is up-regulated in various cancers including prostate and mesothelioma.

MorphoSys plans to use its HuCAL® technology to accelerate the rate of product introductions by Biogenesis which it acquired in January 2005.

Existing Biogenesis customers who are interested in research antibodies are being offered recombinant antibody development services by MorphoSys’s Antibodies by Design division.

"The launch of a series of recombinant research antibodies for sale via the Biogenesis sales catalog is very exciting for us as it demonstrates how quickly the Biogenesis and Antibodies by Design Divisions of MorphoSys are able to respond to new scientific developments and market demands using the speed and flexibility of the MorphoSys HuCAL GOLD® technology,” stated Dieter Lingelbach, Head of Antibodies by Design and Biogenesis.

Advertisement